Plasma cell myeloma refractory
Not yet recruitingA Study of Linvoseltamab Alone and Linvoseltamab with Carfilzomib Compared to Standard Treatment in Adults with Relapsed or Refractory Multiple Myeloma
A Study of Linvoseltamab Alone and Linvoseltamab with Carfilzomib Compared to Standard Treatment in Adults with Relapsed or Refractory Multiple Myeloma
- Disease:Plasma cell myeloma refractory
- Substances:AciclovirBortezomib+10
France- Participants:18–64 years · 65+ years
- Substances:Aciclovir
- Sponsor:Regeneron Pharmaceuticals Inc.








